Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus rhamnosus HN001

What does the research say about Lactobacillus rhamnosus HN001?

3 health outcomes synthesised

Lactobacillus rhamnosus HN001 has been studied across three health outcomes: reduced anxiety, reduced atopic sensitization, and reduced eczema prevalence. The strongest evidence comes from research on reduced anxiety, with 4 studies (3 beneficial, moderate evidence strength) primarily in pregnant and postpartum women, using doses ranging from daily supplementation from enrolment until six months postpartum. Key insights include a significant reduction in clinically relevant anxiety (OR=0.44) in a large RCT, though the evidence base is small and subject to publication bias.

Strongest evidence

  • Reduced Anxiety (moderate evidence): 3 of 4 studies reported beneficial effects, with effect sizes ranging from small to moderate. The largest RCT (n=423) in pregnant and postpartum women found a significant reduction in clinically relevant anxiety (OR=0.44). Doses varied, typically starting from enrolment or 35 weeks gestation and continuing until six months postpartum if breastfeeding.
  • Reduced Atopic Sensitization (moderate evidence): 2 of 3 RCTs showed benefit (one statistically significant, one trending), with effect sizes small to moderate. The most studied dose was 6×10^9 CFU/day, and direct infant administration appeared necessary (maternal-only supplementation was neutral).

Mixed or weaker evidence

  • Reduced Eczema Prevalence (low evidence): Only 1 of 3 RCTs reported a large beneficial effect; 2 well-designed RCTs found no significant effect. The effective dose was 6×10^9 CFU/day, but benefit was observed only in a high-risk cohort with long-term follow-up to age 4 years, while maternal-only supplementation showed no benefit.

Effective dose patterns

Across outcomes, a dose of approximately 6×10^9 CFU/day was used in studies of atopic sensitization and eczema. For anxiety, doses varied and were tied to pregnancy and postpartum timing rather than a fixed daily amount; one study used daily from enrolment until 6 months postpartum, another from 35 weeks gestation until six months if breastfeeding.

Population insights

  • Pregnant and postpartum women are the primary population studied for reduced anxiety.
  • Infants and their mothers, particularly those at high risk for allergic disease, are the focus for atopic sensitization and eczema outcomes. Direct administration to infants appears more effective than maternal-only supplementation.
  • The neutral anxiety study in children suggests benefit may be population-specific to pregnant/postpartum women.

Notable caveats

  • The evidence base for all three outcomes is small (3–4 studies each), so conclusions should be considered preliminary.
  • Clinical literature on anxiety is subject to publication bias (null-result studies less likely to be published).
  • For atopic sensitization and eczema, maternal-only supplementation showed no benefit, implying that infant exposure may be necessary for effect.
  • The eczema result relies on a single large-effect study; two neutral RCTs reduce confidence in the finding.

Frequently asked

  • What is Lactobacillus rhamnosus HN001 good for according to research?
    Research has investigated Lactobacillus rhamnosus HN001 for three outcomes: reduced anxiety, reduced atopic sensitization, and reduced eczema prevalence. The strongest evidence (moderate) supports a beneficial effect on reducing anxiety in pregnant and postpartum women (3 of 4 studies beneficial) and on reducing atopic sensitization in high-risk infants (2 of 3 RCTs beneficial). Evidence for eczema is weaker (low, only 1 of 3 studies beneficial).
  • What dose of Lactobacillus rhamnosus HN001 is typically used in studies?
    For atopic sensitization and eczema, the most studied dose is 6×10^9 CFU per day. For anxiety, doses varied across studies: one used daily supplementation from enrolment until six months postpartum if breastfeeding, another from 35 weeks gestation until six months if breastfeeding. No consistent single dose range has been established across all anxiety studies.
  • Who benefits most from Lactobacillus rhamnosus HN001?
    Pregnant and postpartum women appear to benefit most for reduced anxiety, with one neutral study in children suggesting the effect may be population-specific. For atopic sensitization and eczema, benefit is most evident in high-risk infants (e.g., those with family history of allergic disease) and when the probiotic is administered directly to the infant, not just to the mother during pregnancy and breastfeeding.
  • Are there caveats or limitations in the research on Lactobacillus rhamnosus HN001?
    Yes. The evidence base is small for all outcomes (3–4 studies), so findings are preliminary. For anxiety, publication bias is a concern (null studies less likely to be published). For atopic sensitization and eczema, maternal-only supplementation showed no benefit in one study each, suggesting direct infant administration may be required. The eczema evidence is the weakest, with only one of three RCTs finding a significant effect.
  • Does Lactobacillus rhamnosus HN001 help with anxiety?
    Research suggests a beneficial effect: 3 of 4 studies reported reduced anxiety in pregnant and postpartum women, with the largest RCT (n=423) finding a significant reduction in clinically relevant anxiety (OR=0.44). However, one neutral study in children indicates the benefit may not generalize to all age groups. The evidence is moderate but based on a small number of studies.
  • Does Lactobacillus rhamnosus HN001 help prevent eczema?
    The evidence is mixed. Only 1 of 3 RCTs found a large beneficial effect on reducing eczema prevalence, while two well-designed RCTs reported no significant effect. The positive study used 6×10^9 CFU/day in a high-risk birth cohort with follow-up to age 4 years; maternal-only supplementation showed no benefit. The overall evidence strength is low, so conclusions are preliminary.

Most-studied combinations with Lactobacillus rhamnosus HN001

most supplement research is combination research
Also studied with:Bifidobacterium lactis HN019 (3), Lactobacillus rhamnosus MAK79L08R (2), Bifidobacterium animalis subsp. lactis HN019 (2)
Back to top